PhaseBio Pharmaceuticals P/S ratio

P/S ratio of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of PhaseBio Pharmaceuticals is 48.71 (as of December 30, 2020)
  • P/S ratio for the quarter ending September 29, 2021 was 12.71 (a -16.96% decrease compared to previous quarter)
  • Year-over-year quarterly P/S ratio decreased by -82.14%
  • Annual P/S ratio for 2020 was 48.71 (a -31.55% decrease from previous year)
  • Annual P/S ratio for 2019 was 71.15 (a Infinity% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of PhaseBio Pharmaceuticals

Most recent P/S ratioof PHAS including historical data for past 10 years.

Interactive Chart of P/S ratio of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 12.71 15.31
2020 46.96 48.71
2019 71.15 64.6 191.56 0.0 71.15
2018 0.0 0.0 0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.